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Abstract
Although cell therapy of the failing heart by intramyocardial injections of myoblasts to results
in regenerative benefit, it has also been associated with undesired and prospectively fatal
arrhythmias. We hypothesized that intramyocardial injections of myoblasts could enhance
inflammatory reactivity and facilitate electrical cardiac abnormalities that can be reduced by
epicardial myoblast sheet delivery. In a rat model of ischemic heart failure, myoblast therapy
either by intramyocardial injections or epicardial cell sheets was given 2 weeks after occlu-
sion of the coronary artery. Ventricular premature contractions (VPCs) were assessed,
using an implanted three-lead electrocardiograph at 1, 7, and 14 days after therapy, and 16-
point epicardial electropotential mapping (EEPM) was used to evaluate ventricular arrhyth-
mogenicity under isoproterenol stress. Cardiac functioning was assessed by echocardiog-
raphy. Both transplantation groups showed therapeutic benefit over sham therapy.
However, VPCs were more frequent in the Injection group on day 1 and day 14 after therapy
than in animals receiving epicardial or sham therapy (p < 0.05 and p < 0.01, respectively).
EEPM under isoproterenol stress showed macroreentry at the infarct border area, leading
to ventricular tachycardias in the Injection group, but not in the myoblast sheet- or sham-
treated groups (p = 0.045). Both transplantation types modified the myocardial cytokine ex-
pression profile. In animals receiving epicardial myoblast therapy, selective reductions in
the expressions of interferon gamma, interleukin (IL)-1β and IL12 were observed, accompa-
nied by reduced infiltration of inflammatory CD11b- and CD68-positive leukocytes, com-
pared with animals receiving myoblasts as intramyocardial injections. Intramyocardial
myoblast delivery was associated with enhanced inflammatory and immunomodulatory re-
activity and increased frequency of VPCs. In comparison to intramyocardial injection, the
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epicardial route may serve as the preferred method of skeletal myoblast transplantation to
treat heart failure.
Introduction
Cell therapy of ischemic heart failure with skeletal myoblasts initiated the first hype in cardiac
cell transplantation more than a decade ago [1–4]. Transplanted myoblasts populated the heart
and reversed ventricular remodeling through secretion of paracrine mediators [5]. In addition,
isolation and expansion of autologous myoblasts did not involve complicated laboratory proce-
dures, genetic manipulation, or allogeneic material, allowing swift application in the clinical
arena. Since then, several studies—including large-scale randomized clinical trials—have impli-
cated a limited therapeutic efficacy and possibly fatal arrhythmogenicity for myoblast cell ther-
apy [6–11]. These undesired effects were explained, at least in part, by inconsistencies in cell
transplantation protocols (number of myoblasts transplanted, methods of myoblast delivery
into the heart) or target heart pathology that could fundamentally affect the behavior of the
transplanted myoblasts.
The route of delivery plays an important role in the arrhythmogenicity of cell transplanta-
tion in chronic heart failure [12]. Cell delivery by intramyocardial injections causes formation
of heterogenic cell clusters that consist of the transplanted cells and infiltrated host cells, lead-
ing to formation of potential areas of electrical reentry that may cause ventricular tachyar-
rhythmias [13]. On the other hand, epicardial transplantation of scaffold-free cell sheets on the
surface of the heart promotes survival of the transplanted cells and enhances the therapeutic ef-
fects of myoblast delivery [4]. A recent report by Narita et al. demonstrated a low level of
arrhythmogenicity for cell-sheet transplantation [14]. We hypothesized that selective modifica-
tion of myocardial inflammatory reactivity by direct cell injections into myocardial tissue may
be associated with ventricular arrhythmias. Moreover, we investigated whether such inflamma-
tory reactivity and associated arrhythmias could be avoided by epicardial myoblast sheet trans-
plantation without compromising therapeutic efficacy.
Materials and Methods
All animals were maintained and study procedures performed in accordance with the "Princi-
ples of Laboratory Animal Care" formatted by the National Society for Medical Research. All
animal experiments were approved by the Local Ethics Committee of Osaka University Hospi-
tal. All procedures and measurements were performed blinded to the treatment methods
when applicable.
Primary skeletal myoblasts and myoblast sheets
Primary skeletal myoblasts were isolated from the tibial anterior muscles of 3-week-old male
Lewis rats (n = 10, weight 100–150 g), as described previously [2]. Briefly, the muscles were ex-
cised and washed with phosphate-buffered saline (PBS). After meticulous removal of nonmus-
cle tissues, the muscles were weighed, minced, and enzymatically digested with collagenase
(Gibco BRL, Rockville, MD, USA), 5 mg/mL at 37°C for 40 min. The cells were collected and
resuspended in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco BRL) with 20% fetal bo-
vine serum (FBS) and 1% penicillin-streptomycin (Gibco BRL). The cells were plated in
100-mm collagen-coated culture dishes (Iwaki Co. Ltd., Tokyo, Japan) and cultured at 37°C in
a humidified atmosphere containing 5% CO2. Poly-N-isopropylacrylamide (PIPAAm)
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thermoresponsive polymer-coated culture dishes were used to construct the myoblast sheets
[15]. The surfaces of these dishes are hydrophobic at an incubator temperature of 37°C, but be-
come hydrophilic at temperatures less than 20°C. A total of 9 × 106 cells in suspension were
plated on the PIPAAm cell-culture dish and incubated for 1–2 days, as outlined above. There-
after, the cell sheets spontaneously detached from these dishes at 20°C in 1 h. For the injections,
a myoblast single-cell suspension of 9 x 106 cells was used.
Model of ischemic cardiomyopathy and skeletal myoblast
transplantation
Female Lewis rats 8 weeks of age (175–225g) underwent permanent ligation of the left anterior
descending (LAD) artery at the level of the left atrial appendage through the 4th intercostal
space (n = 70) [16]. Two weeks after the LAD ligation, a rethoracotomy through the 5th inter-
costal space was performed for myoblast transplantation. The rats were randomized into three
groups: 1) direct intramyocardial injection of 9 x 106 cells in 100 μl PBS, using a 31-gauge nee-
dle (Injection group, n = 17), 2) epicardial application of a myoblast sheet, consisting of 9 x 106
cells, on the infarct area (Sheet group, n = 18), or 3) sham operation (Control group, n = 19).
The sham-operated rats underwent induction of infarction by LAD ligation and a rethoracot-
omy after 2 weeks without cell transplantation.
Echocardiography
Fig 1 illustrates the experimental protocol. Echocardiography (ECG) was performed before the
LAD ligation as well as before and 2 weeks after myoblast transplantation. The rats were anes-
thetized by 2% isoflurane inhalation for transthoracic ECG, and the end-diastolic and end-sys-
tolic diameters (LVEDD and LVESD, respectively) of the left ventricles (LVs) were measured
at the level of the papillary muscles, using the M-mode. The two-dimensional mode was used
to assess the LV ejection fraction (LVEF).
Telemetric electrocardiography
Each animal was implanted with a three-lead electrocardiographic device (Unique Medical Co.
Ltd, Tokyo, Japan) into its back before myoblast transplantation at 2 weeks after LAD ligation.
The electrodes were placed at shoulder level and at the midline of the nape. A 6-h electrocar-
diographic assessment was performed on all animals on days 1, 7, and 14 after treatment to re-
cord the ECG and signal intensification, which were analyzed by Unique Medical Acquisition
Fig 1. Study protocol timeline.Myoblast cell therapy as intramyocardial injections or epicardial sheets was administered 2 weeks after induction of heart
failure and ischemia by ligation of the left anterior coronary artery (Myocardial infarction). Electrocardiography (Holter) was monitored constantly, using
implanted Holter monitors, and specific recordings were made on days 1, 7, and 14 after cell therapy administration. Echocardiography (Echo), as measured
first before and then 2 weeks after myoblast transplantation, was used to evaluate therapy efficacy. Epicardial electropotential mapping (EEPM) was
performed 14 days after therapy administration.
doi:10.1371/journal.pone.0123963.g001
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Software (Unique Medical Co. Ltd.). The number of ventricular premature contractions
(VPCs) was calculated as the percentage of all ventricular beats. Multiform consecutive VPCs
and ventricular tachycardias (VTs) were quantified as the number of events during a
24-h period.
Epicardial electropotential mapping under isoproterenol stress
After the 14-day follow-up (Fig 1), 16-point epicardial electropotential mapping (EEPM) was
performed with an epicardial multielectrode probe (Unique Medical Co. Ltd.). This probe con-
sists of 16 needle electrodes, molded in a 5 x 5-mm silicone plate in a quadrangular fashion.
Each electrode’s electric potential was recorded at 2.0-ms intervals. These recordings were per-
formed at four points in the infarct border area before and after administration of the proar-
rhythmic drug, isoproterenol (0.1 μmol/L, Sigma-Aldrich, Tokyo, Japan) by transapical
bolus injection.
Histological studies
After the 14-day follow-up, following ECG and electrocardiography assessments, the rats were
euthanized under anesthesia by potassium chloride injection through the apex of the heart.
The hearts were harvested and the LVs sliced into four pieces along the short axis. The speci-
mens were fixed with 4% formaldehyde and embedded in paraffin. Sections (10 μm thick) were
examined by immunofluorescence for leukocyte/monocyte infiltration by cluster of differentia-
tion (CD)11b (Abcam plc, Cambridge, UK) expression with 4',6-diamidino-2-phenylindole
(DAPI, Sigma-Aldrich) counterstaining. Monocyte/macrophage infiltration was further con-
firmed with immunohistochemical staining of CD68. Antigen retrieval was done at 95°C for
1 h in 10 mM citrate buffer and endogenous peroxidase was blocked by 0.5% H2O2-treatment
for 30 min. The sections were then blocked in 10% normal goat serum (Vector Laboratories,
Peterborough, UK), followed by incubation with primary antibody against CD68 (Abcam,
1:100 dilution) and biotinylated secondary antimouse antibody (Vector Laboratories). The sec-
tions were then further treated, using the Vectastain Elite ABC kit followed by the 3-amino-
9-ethylcarbazole (AEC) Peroxidase Substrate Kit (Vector Laboratories). Prior to mounting, the
sections were counterstained with eosin. Six images per myocardial section were used (20x
magnification) to calculate the mean values of the positively stained area. The images were ana-
lyzed, using ImageJ software (imagej.nih.gov/ij/).
Evaluation of myocardial gene expression by real-time PCR
Immediately after harvesting, the midventricle infarct border area was cut and immersed in
RNAlater RNA-Stabilization Reagent (Qiagen, Hilden, Germany) to stabilize the RNA (n = 18,
six animals from each group). The total RNA was then isolated (RNeasy Mini Kit, Qiagen) and
purified (RNase-Free DNase Kit, Qiagen). Reverse transcription was executed with 1 μg of total
RNA (Omniscript Reverse Transcriptase, Qiagen). The sets of primers and a TaqMan probe,
which was labeled with a reporter dye, fluorescein amidite (FAM) at the 50-end and a quencher
dye, carboxytetramethylrhodamine (TAMRA) at the 30-end, were designed with Primer Ex-
press software (Life Technologies, ThermoFisher, Waltham, MA, USA). The real-time poly-
merase chain reaction (rtPCR) was carried out, using the ABI PRISM 7700 Sequence Detection
System with TaqMan Universal PCR Master Mix (Applied Biosystems). Absolute quantifica-
tion was used to determine the number of fragments (copy number), using external standards.
A PCR product containing the target sequence was used as the standard and was evaluated at
seven different copy numbers. Relative quantification was calculated by the ratio between the
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amount of target and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) within the same
sample. The sequences for the primers and probes used in this study are listed in S1 Table.
Statistical analysis
All values are expressed as mean ± standard error of the mean (SEM). The differences between
groups were compared, using one-way analysis of variance (ANOVA) and Newman-Keul’s
posttest with multiple comparisons. Contingency tables were analyzed with Fisher’s test (mor-
tality and VT’s). Pairwise comparisons were performed using student’s t-test. Statistical analy-
ses were performed with Graph Pad Prism 4.0 (GraphPad Software Inc., San Diego, CA, USA).
A value of p< 0.05 was considered significant.
Results
Mortality following the LAD ligation was 14% (10/70). All mortality occurred during or soon
after the surgical procedure, due to surgical stress. Prior to randomization, six rats were exclud-
ed from the study, due to the lack of infarction in the pretreatment ECG. Mortality following
the surgery for transplantation therapy was 14% (3/21) in the Sheet group, 19% (4/21) in the
Injection group, and 14% (3/22) in the sham rethoracotomy group, with no statistical differ-
ences between the groups.
Therapeutic efficacy of myoblast transplantation
To evaluate the regenerative therapeutic efficacy of the treatment modalities, LVEF, LVEDD,
and LVESD were assessed before and 2 weeks after the treatment, using transthoracic ECG
(Fig 2). LVEF was significantly increased in the Sheet (40 ± 5–50 ± 7%) and the Injection
(41 ± 6–44 ± 7%) groups at follow-up, but was decreased in the Sham group (43 ± 5–36 ± 7%)
(Fig 2A). A similar result was found for fractional shortening (FS) (Fig 2B). LVEDD increased
in the Control group (6.1 ± 0.9–6.9 ± 0.7 mm), while this increase was not observed in the
Sheet (6.5 ± 0.4–6.8 ± 0.7 mm) or Injection (6.5 ± 0.4–6.8 ± 0.7) groups (Fig 2C). Fig 2D shows
representative hematoxylin-eosin-stained images of the myocardium at the 14-day follow-up
from each group to demonstrate the effect of myoblast transplantation on remodeling of the
LV.
Reduced spontaneous arrhythmias following epicardial myoblast sheet
transplantation
A 6-h continuous ECG monitoring was performed, using telemetry on days 1, 7, and 14 after
the myoblast transplantations. The Injection group showed more VPCs than the Control
group on days 1 and 14, while the Injection group showed more VPCs than the Sheet group on
days 7 and 14 (Fig 3). There was no significant difference between the Sheet group and the
Control group: (Sheet: 15.6 ± 11.2 on day 1, 3.1 ± 2.2 on day 7, and 1.0 ± 1.0 on day 14; Injec-
tion: 41.3 ± 16.4 on day 1, 35.2 ± 13.3 on day 7, and 71.5 ± 29.8 on day 14; Control: 1.7 ± 1.2 on
day 1, 18.0 ± 13.5 on day 7, and 1.4 ± 1.0 on day 14. No VTs were detected in any of the rats
during the Holter recordings.
Intramyocardial myoblast injection-induced formation of electrical
reentry
EEPM showed no significant differences in QRS wavelength, activation/repolarization inter-
vals, or refractory times among the groups. However, two rats of the Injection group showed
an area of macroreentry at the infarct border where the myoblasts were injected (Fig 4). In
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PLOS ONE | DOI:10.1371/journal.pone.0123963 April 10, 2015 5 / 15
both of these rats, isoproterenol administration caused a VT that developed from the site of the
reentry. In two other rats of the Injection group, isoproterenol administration induced VT
without clear detection of an area of reentry. The Sheet or Control groups did not show any
macroreentry areas or induce VTs by isoproterenol administration (p = 0.045).
Leukocyte infiltration and inflammatory gene expression in the
myocardium
Immunofluorescent staining for CD11b (p< 0.001) and immuhistochemistry for CD68
(p< 0.05, Fig 5) detected less macrophage accumulation in the infarct border areas of the
Sheet and Control groups than in that of the Injection group at the 14-day follow-up.
Fig 2. Panel A: Epicardial transplantation of myoblast sheets (Sheet group, n = 18) significantly improved the left ventricular ejection fraction (EF).
In sham-treated animals (Control group, n = 19), EF decreased markedly during the 2-week follow-up. This decrease in EF was attenuated by myoblast
intramyocardial injection therapy (Injection group, n = 17). Panel B: Significant improvement in fractional shortening (FS) was observed in the Sheet group.
FS significantly deteriorated in the Control group, while in the Injection group this decrease was attenuated. Panel C: As a measure of left ventricular
remodeling, the left ventricular end-diastolic diameter (LVEDD) decreased in the Sheet group and increased in the Control group. In the Injection group, the
LVEDD remained similar to the baseline value. Panel D: Representative hematoxylin-eosin-stained paraffin-embedded sections of the heart on the
midventricular short axis from each group. The myocardium in the Sheet group demonstrated less remodeling of the left ventricle than the Control group. A
similar, but less pronounced, effect on remodeling was evident in the Injection group. * p < 0.05, ** p < 0.01 Sheet group vs. Control group; † p < 0.05, ††
p < 0.01 Sheet group vs. Injection group.
doi:10.1371/journal.pone.0123963.g002
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Inflammatory gene expression in the myocardium was evaluated, using rtPCR. Fig 6 dem-
onstrates the expression patterns of interferon (IFN)γ, IL1β, IL12, IL15, IL2R, inducible protein
10/chemokine (C-X-C motif) ligand 10 (IP10/CXCL10), monocyte chemoattractant protein 1/
chemokine (C-C motif) ligand 2 (MCP1/CCL2), macrophage inflammatory protein 1α/chemo-
kine (C-C motif) ligand 3 (MIP1α/CCL3), MIP1β/CCL4, and MIP1γ/CCL9, which differed sta-
tistically between animals in the Injection group and those in the Control group. The
expressions of IL6 and IL10 in the myocardium remained low in all groups, and there were no
differences between the groups. The expression of connexin 43 (CNX43) was not significantly
different statistically among the groups. Interestingly, the selective expressions of IFNγ, IL1β,
and IL12 genes were significantly greater in the Injection group than in the Sheet group. The
expression levels of IL1β and IL12 in the Injection group did not differ from the relatively low
expression levels observed in the Control group.
Discussion
Using a rat model of ischemic heart failure, we show here that epicardial transplantation of
myoblast sheets prevents the undesired development of spontaneous ventricular
Fig 3. Ventricular premature contractions (VPCs) after epicardial myoblast sheet transplantation
(Sheet group, n = 18) or intramyocardial myoblast injections (Injection group, n = 17). The Control
group (n = 19) received, instead of myoblast therapy, a sham operation 2 weeks after myocardial infarction.
Electrocardiography was monitored continuously. The number of VPCs was significantly higher in the
Injection group on days 1 (p < 0.05) and 14 (p < 0.01) after myoblast transplantation than in the Control group
(*) and significantly higher on days 7 (p < 0.05) and 14 (p < 0.01) than in the Sheet group (†). There was no
ventricular tachycardia recorded in any of the animals.
doi:10.1371/journal.pone.0123963.g003
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tachyarrhythmias associated with cell delivery by intramyocardial injections. Reentry tachycar-
dias provoked by an adrenergic isoproterenol challenge were observed only in the group treat-
ed with skeletal myoblast injections. Moreover, myoblast injections—but not epicardial
deposition—increased the myocardial inflammatory infiltrate (as evidenced by the number of
CD11b- and CD68-positive cells) and increased the gene expression of IL1β, IL12, and IFNγ
proinflammatory cytokines. Therapy of ischemic heart failure by epicardial myoblast sheets
improved cardiac functioning, with superior efficacy over myoblast therapy by intramyocardial
injections.
Intramyocardial myoblast delivery generates cell clusters of transplanted cells, results in ac-
cumulation of host-derived inflammatory cells, and induces ventricular tachyarrhythmias
[8,17]. The role played by the inflammatory process in these myocardial electrical abnormali-
ties has remained unclear. Myocardial infarction is closely linked to inflammation and in-
creased production of inflammatory cytokines [18]. Intramyocardial injections may induce
host myocardial injury and/or death of injected cells, processes that signal for initiation and ac-
celeration of the inflammatory process in the longer run. Our results demonstrate that in-
creased or sustained inflammatory leukocyte infiltration and selective expression of the
proinflammatory cytokines IL1β, IL12, and IFNγ are linked to myoblast intramyocardial deliv-
ery and are associated with the VPCs induced by this type of therapy administration. Of note,
isoproterenol-stimulated electrical macroreentry, as visualized here using EEPM in two myo-
blast-injected rats, suggests that the inflammatory infiltrate or sustained production of IL1β/
IL12/IFNγ positively influences the process of macroreentry. By contrast, epicardial myoblast-
sheet implantation did not induce accumulation of macrophages and, importantly, neither pro-
duced an electrical macroreentry area nor enhanced the ventricular tachyarrhythmic potential.
To achieve clinical relevance with timing of cell transplantation, myoblast therapies were
administered 14 days after the induction of myocardial infarction. In this model, therapeutic
benefit was more evident following epicardial myoblast sheet implantation than direct myo-
blast injection. Since the expression profiles of several cytokines were similar between the Injec-
tion and Sheet groups, the difference in therapeutic effect likely resulted from differential
survival of myoblasts and the magnitude of acute inflammation postimplantation. Since epicar-
dial cell transplantation increases cell survival in comparison to cell injections [19], its greater
therapeutic effects can be mediated by increased amounts of myoblast-derived cardioprotective
paracrine factors. Although direct myocardial cell injection up-regulates cardioprotective fac-
tors in the myocardium, it also induces up-regulation of the proinflammatory cytokines, in-
cluding IL1β, that adverse affect the contractile function of cardiomyocytes [20] or serve to
exacerbate myocardial fibrosis [21]. Moreover, myoblast-sheet transplantation results in higher
myocardial graft retention and more even graft distribution at the site of transplantation, as op-
posed to injection-associated formation of cell clusters and cell localizations in the lungs [14].
As outlined above, the cytokines observed here as being selectively induced by intramyocar-
dial myoblast injections were IL1β, IL12, and IFNγ. Taken together with increased CD11b-/
CD68-positive leukocyte infiltration, a hypothesis of macrophage subtype modulation by these
therapy types can be postulated. Increased production of IL12 from dendritic cells and mono-
cytes in response to intracardiac myoblast delivery by injections could stimulate helper 1 T
Fig 4. Electropotential mapping was performed epicardially with a 16-needle probe at 2.0-ms
intervals. In the premedication maps, one cardiac R-R-cycle is shown (images from 18 ms to 218 ms) at a
normal rat heart rate (300 beats per minute, bpm). An area of reentry can be seen as red coloration in the
middle of the border area measured. Sixty seconds after a bolus injection of isoproterenol, the reentry area
was observed, while 120 s after the isoproterenol bolus, a full ventricular tachycardia has developed, with a
heart rate of approximately 6000 bpm.
doi:10.1371/journal.pone.0123963.g004
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Fig 5. Panels A-C: Representative immunofluorescence images of CD11b-expression, with DAPI counterstaining of the nuclei of the myocardium
2 weeks after myoblast cell therapy (4 weeks after myocardial infarction). Infiltration of CD11b-positive cells by epicardial transplantation (panel A) was
similar to that of the Control group (panel C). Panel D: Clusters of CD11b-positive inflammatory cells can be seen in the myocardium of the Injection group at
a higher magnification. Panel E shows densitometry quantitation of CD11b-expression in the various groups (n = 6). In the group receiving intramyocardial
injections, an increased leukocyte infiltrate was evident in comparison to the Control or Sheet groups (*** p < 0.001 vs. Injection group). Panels F-I show
CD68-staining similar to that of CD11b. Quantitation of the CD68-positive area showed increased CD68-positive cell infiltration in the Injection group in
comparison to the Sheet and Control groups (panel J, * p < 0.05 for both comparisons).
doi:10.1371/journal.pone.0123963.g005
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(TH1) and natural killer (NK) cells to produce IFNγ, which in turn could shift macrophage po-
larity towards an IL1-producing proinflammatory M1 subtype [22]. Predominance of this sub-
type, implicated in the acute phase of injury after myocardial infarction [23,24] could then
limit the therapeutic potential of myoblasts. In turn, attenuating the host myocardial IL12 re-
sponse by epicardial myoblast delivery could drive the myocardial cytokine profile into one
serving a more regenerative and restorative function [24]. This would be suggested by the dual
nature of MCP1 in the heart [25,26].
Fig 6. Myocardial gene expressions of inflammatory genes in the sham-treated (Control group, n = 6)
and in the groups receiving myoblast cell therapy as intramyocardial injections (Injection group,
n = 6) or epicardial cell sheets (Sheet group, n = 6). Data are expressed as mean ± SEM. * p < 0.05, **
p < 0.01 compared with the Control group. † p < 0.05 compared with the Injection group.
doi:10.1371/journal.pone.0123963.g006
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IL1 has been directly implicated in heart failure pathogenesis [27,28], negative modulation
of cardiomyocyte contractility, and electrical conduction [29,30]. This cytokine is produced in
response to tissue damage, primarily by tissue-infiltrating monocytes [30]. Importantly, sup-
pression of myocardial IL1 signaling can improve the survival of grafted myoblasts, suggesting
an essential role for suppression of the IL1 pathway in myoblast therapy [31]. Therefore, selec-
tive modulation of this cytokine, as seen here by choice of transplantation technique, may help
to attenuate its adverse effects on myocardial functioning in cell transplantation. The role of
IL1 in adverse remodeling and in both direct and indirect (e.g. pathological cardiac morpholo-
gy, stimulation of immunological and inflammatory signaling) modification of cardiac
electrophysiological conduction circuitry deserves further investigation.
The selective induction of IL12 by intramyocardial injections of myoblasts, as evidenced
here, should be evaluated further. IL12 is produced mainly by cells of the immune system, such
as monocytes and dendritic cells [32], and it regulates the functioning of NK cells and T-cells
[32]. Increased IL12 after intramyocardial myoblast delivery, but not after epicardial cell depo-
sition, may reflect a selective innate host response against the injected cells. In fact, the block-
ade of IL12 attenuates chronic rejection in cardiac transplantation [33], suggesting that the
IL12 host response may accentuate myocyte death by immunological mechanisms in intra-
myocardial delivery. Although previous studies have reported little of the immune response-re-
lated inflammation we showed in the model used here, our study may have been limited by the
hostimmune response, due to gender-mismatched transplantation [34,35]. However, the lack
of an IL12 response against epicardially transplanted cells, as we observed here, may enhance
survival of the transplanted cells and favorably modulate the myocardial inflammatory signal-
ing networks and immunological injury [36].
We were unable to repeat the finding of Coppen et al. [37] that secreted IL1β from the sur-
viving skeletal myoblasts globally down-regulates myocardial CNX43 expression and conse-
quently induces ventricular tachyarrhythmia following transplantation of skeletal myoblasts in
a chronic heart failure model. In concert with that study, however, we found up-regulation of
IL1β—but not CNX43 as stated above—after myoblast injection, but not after cell-sheet im-
plantation. This may have been due to differences in experimental models, such as magnitude
of the myocardial infarction, timing of the treatment, or rat strain. As a limitation of our study,
we did not measure direct cell-cell coupling between native cardiomyocytes and transplanted
myoblasts.
This study is further limited by the fact that we compared two administration routes and
did not include various other means of cell delivery, such as intracoronary infusion. It needs to
be pointed out that—in concert with our results on the therapeutic inferiority of intramyocar-
dial delivery—Li et al. (2011) demonstrated that intracoronary cell delivery also resulted in
greater therapeutic effect and more uniform cell distribution than intramyocardial injections
[38]. Further studies are warranted to directly compare the effects of cell-sheet and intracoron-
ary infusion techniques. Moreover, a combination approach with cell sheets first transplanted
epicardially during bypass surgery, followed by cells delivered periodically using a transcatheter
infusion approach, possibly even in a repeated manner over time, could be envisioned as pro-
viding synergistic and longer-lasting effects. Another limitation of our study is the lack of fibro-
sis quantitation. Memon et al. previously showed that the epicardial delivery route results in
reduced fibrosis in contrast to intramyocardial injections [2]. The reduced inflammatory re-
sponse associated with the epicardial delivery route may contribute to the antifibrotic
effect reported.
In summary, our results demonstrate that injection of myoblasts into the LV after resolution
of the acute first phase of inflammation induced by myocardial ischemia incites an inflamma-
tory reaction characterized by CD11b-/CD68-positive leukocyte infiltration that is not
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observed in epicardial delivery of myoblasts. Epicardial transplantation also significantly re-
duced both VPCs and the expressions of IL1β, IL12, and IFNγ in the myocardium. As a prelim-
inary finding warranting further investigation, this result suggests a role for these cytokines
and putative modulation of leukocyte trafficking in the induction of arrhythmogenicity during
cell transplantation. We demonstrate here that epicardially transplanted myoblast sheets lack
the arrhythmogenic and inflammatory activity that is induced when myoblasts are delivered
intramyocardially. Our results thus indicate that epicardial delivery of myoblasts has a positive
safety profile and that this method thus has ideal properties as a cellular therapy modality for
patients with ischemic heart failure.
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